OCC Orthocell sees US Remplir sales on immediate horizon as distro deal locked in Orthocell (ASX:OCC) has locked in a U.S. distributor deal for its flagship product and biotech punter favourite Remplir, leaving the company confident U.S. sales are about to kick off. Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from througho... Jonathon Davidson 11 hours ago ASX News Healthcare Technology Scientific & Technical Instruments
RCE Recce adds 20 more people to trial for R327G foot gel Recce Pharmaceuticals Ltd has received Human Ethics Approval to add 20 more patients with diabetic foot infections to its clinical trial Caroline Smith 1 day ago ASX News Healthcare Biotechnology
BP8 Under the Seaweed: The hidden potential of naturally occurring marine waste Seaweed isn’t something we inherently think of as valuable (perhaps we don’t think of it at all, unless it gets caught in our feet while we’re swimming).However, in recent years, marine algae have become a sought-after commodity group across the wor... Caroline Smith 2 days ago ASX News Healthcare Biotechnology
TRU TruScreen launches cervical screening program in Vietnam TruScreen Group Ltd recently launched a program aiming to screen 260,000 women for cervical cancer using its AI-enabled technology Caroline Smith 2 days ago ASX News Healthcare Technology Scientific & Technical Instruments
CU6 Clarity scribes deal on delivery of copper 64 isotopes Clarity Pharmaceuticals Ltd has seen its share price leap after it announced a deal with Nusano to deliver Cu-64 isotopes Caroline Smith 6 days ago ASX News Healthcare Biotechnology
IRX InhaleRX sets up Phase 1 trial for panic disorder inhaler InhaleRX Ltd has executed a Study Order with iNGENū CRO Pty Ltd to oversee its Phase 1 trial for cannabidiol inhaler IRX-616a Caroline Smith 6 days ago ASX News Healthcare Technology Scientific & Technical Instruments
FRE 'Expansion' the watchword in Firebrick's sales-heavy quarter Firebrick Pharma Ltd has recorded a busy March quarter for 2025, marked by its move into retailing Nasodine in Singapore Caroline Smith 16 Apr 2025 14:38 (AEST) ASX News Healthcare Biotechnology
CCO The Calmer Co's Fiji Kava product hitting Woolworths stores The Calmer Co International Ltd is expanding its dominance in Australia's retail sector with the entry of Fiji Kava into Woolworths Caroline Smith 16 Apr 2025 12:56 (AEST) ASX News Consumer Cyclical Healthcare Drug Manufacturers - Major
CCO The Calmer Co inks deal with Woolworths The Calmer Co. (ASX:CCO) has inked a huge new agreement with supermarket giant Woolworths (ASX:WOW) which will see the company’s 50-gram Instant Kava hit shelves in Australia as soon as the middle of the year.Listen to the HotCopper podcast for in-depth discussions and insights on... Isaac McIntyre 16 Apr 2025 09:59 (AEST) ASX News The Watchlist Healthcare Drug Manufacturers - Major
PME Pro Medicus inks R&D agreement with UCSF for Visage AI Accelerator Pro Medicus Ltd has entered a multiyear collaboration with UCSF for research and development for the AI platform Caroline Smith 15 Apr 2025 14:17 (AEST) ASX News Healthcare Technology Medical Devices AI
NUZ Neurizon Therapeutics announces strong safety results in latest study Drug candidate NUZ-001 has shown strong safety characteristics in its latest human 3D brain model study, Neurizon Therapeutics (ASX:NUZ) has confirmed this week.Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify,... Isaac McIntyre 14 Apr 2025 14:30 (AEST) ASX News The Watchlist Healthcare Biotechnology
BP8 BPH Global pens offtake agreement with China-based manufacturer BPH Global (ASX:BP8) has this week signed a significant seaweed offtake agreement with Quanzhou Bailijie Biotechnology, a Chinese carrageenan producer.Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, an... Isaac McIntyre 14 Apr 2025 14:25 (AEST) ASX News The Watchlist Healthcare Biotechnology
NEU FDA OK for Neuren's first ever Phase 3 trial in children with Phelan-McDermid syndrome Neuren has popped 20% as the FDA greenlights its upcoming Phase 3 trial in children with Phelan-McDermid syndrome. Jonathon Davidson 14 Apr 2025 12:11 (AEST) ASX News Healthcare Biotechnology